CHL Medical Partners
VC Fund
Stamford, United States
CHL Medical Partners is a VC fund in Stamford focused on Biotechnology and Health Care. CHL Medical Partners, an American venture capital firm, invests in biotechnology, molecular diagnostic, and medical device companies.
- Total investments:
- 33
- Last investment:
- Lead investor:
- 30%
Last updated:
For AI agents: llms.txt
Industries CHL Medical Partners invests in
BiotechnologyHealth CareMedicalPharmaceuticalTherapeutics
Stages CHL Medical Partners invests in
Series BSeries CSeries DSeries AFunding Round
Countries CHL Medical Partners invests in
United States
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Timothy F.Howe
|
|||
Jeffrey J. Collinson
|
|||
Investment Focus
Industry
- Biotechnology 14 (42%)
- Health Care 12 (36%)
- Medical 7 (21%)
- Pharmaceutical 5 (15%)
- Therapeutics 3 (9%)
Stage
- Series B 7 (21%)
- Series C 6 (18%)
- Series D 5 (15%)
- Series A 4 (12%)
- Funding Round 3 (9%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Timothy F.Howe
Founder & Partner
|
Founder & Partner | Total investments: 0 | Find email | |
|
Jeffrey J. Collinson
Partner
|
Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Mevion Medical Systems
|
Mevion Medical Systems, Inc. (formerly Still River Systems, Inc.) is a radiation therapy company dedicated to advancing the treatment of cancer. As the pioneering developer of modern proton therapy systems, Mevion provides innovative, safe, and effective solutions by transforming advances in medical technology and science into practical clinicalreality.Mevion’s flagship product, the MEVION S250 Proton Therapy System, is designed to preserve all of the treatment benefits of traditional proton therapy systems while removing the obstacles of size, cost, and complexity. Realizing this vision, Mevion has forever changed the economics and accessibility of proton therapy worldwide.Founded in 2004, Mevion is a privately held company headquartered in the Boston metropolitan area with international offices in the United Kingdom and Japan. | $200M / Private Equity / Aug 04, 2014 | |
Vascular Pathways
|
Vascular Pathways, founded by Amir Belson, M.D., is a privately held medical device company focused on commercializing the Rapid IntraVascular Start (RIVS) catheter, an FDA cleared device enabling rapid, safe and successful peripheral IV insertion. | $5M / Debt Financing / Jun 24, 2014 | |
|
Mevion Medical Systems
|
Mevion Medical Systems, Inc. (formerly Still River Systems, Inc.) is a radiation therapy company dedicated to advancing the treatment of cancer. As the pioneering developer of modern proton therapy systems, Mevion provides innovative, safe, and effective solutions by transforming advances in medical technology and science into practical clinicalreality.Mevion’s flagship product, the MEVION S250 Proton Therapy System, is designed to preserve all of the treatment benefits of traditional proton therapy systems while removing the obstacles of size, cost, and complexity. Realizing this vision, Mevion has forever changed the economics and accessibility of proton therapy worldwide.Founded in 2004, Mevion is a privately held company headquartered in the Boston metropolitan area with international offices in the United Kingdom and Japan. | $55M / Private Equity / Jun 25, 2013 | |
Ambra Health
|
Ambra Health is a medical data and image management SaaS company. Intuitive, flexible, scalable, and highly interoperable, the Ambra cloud platform is designed to serve as the backbone of imaging innovation and progress for healthcare providers. It empowers health systems such as Memorial Hermann, Stanford Children’s Health, and New England BaptistHospital as well as radiology practices, subspecialty practices, and clinical research organizations to dramatically improve imaging and collaborative care workflows. | $5M / Series B / May 16, 2012 | |
OpGen
|
Headquartered in Rockville, Maryland, OpGen (NASDAQ:OPGN) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. OpGen, along with its subsidiaries, Curetis and Ares Genetics, develop and commercialize molecular microbiology solutions to help guide clinicians with morerapid and actionable information about life threatening infections to improve patient outcomes. Our innovative approaches to infectious disease diagnostics consist of highly multiplexed syndromic molecular panels, and next-generation sequencing combined with smart bioinformatics and artificial intelligence to address the global threat of antimicrobial resistance (AMR). By integrating these capabilities, we provide unique rapid molecular diagnostic products and services that help to dramatically transform patient care by using precision medicine to guide antibiotic therapy selection and optimize the treatment of life-threatening drug-resistant infections, improve antibiotic stewardship, and decrease the spread of multidrug-resistant microorganisms (MDROs).OpGen Community (Linkedin Group) provides an accessible environment to share information, exchange questions and best practices using OpGen’s technologies in a variety of applications. | $17M / Series C / Mar 07, 2012 | |
|
Mevion Medical Systems
|
Mevion Medical Systems, Inc. (formerly Still River Systems, Inc.) is a radiation therapy company dedicated to advancing the treatment of cancer. As the pioneering developer of modern proton therapy systems, Mevion provides innovative, safe, and effective solutions by transforming advances in medical technology and science into practical clinicalreality.Mevion’s flagship product, the MEVION S250 Proton Therapy System, is designed to preserve all of the treatment benefits of traditional proton therapy systems while removing the obstacles of size, cost, and complexity. Realizing this vision, Mevion has forever changed the economics and accessibility of proton therapy worldwide.Founded in 2004, Mevion is a privately held company headquartered in the Boston metropolitan area with international offices in the United Kingdom and Japan. | $45M / Jan 24, 2012 | |
Valeritas
|
Valeritas is a medical technology company committed to developing and commercializing innovative drug delivery solutions that contribute to clinical and humanistic outcomes for patients, with an initial focus on the treatment of diabetes. Valeritas' medical technologies portfolio is headlined by the h-Patch technology. The first use of theh-Patch technology will be the V-Go disposable insulin delivery device for continuous delivery both at a preset basal rate and for on-demand bolus dosing at mealtimes.The V-Go is a simple-to-use, once-daily, disposable insulin delivery device that provides a preset basal rate and on-demand bolus dosing for mealtime coverage via a mealtime insulin. The V-Go will enable the millions suffering from Type 2 diabetes to conveniently and discreetly deliver insulin throughout the day bolus dose on-demand around mealtimes.The h-Patch technology is also being developed to serve as a launching platform for applications across a wide spectrum of medical needs. | $150M / Series C / Sep 12, 2011 | |
|
Ambra Health
|
Ambra Health is a medical data and image management SaaS company. Intuitive, flexible, scalable, and highly interoperable, the Ambra cloud platform is designed to serve as the backbone of imaging innovation and progress for healthcare providers. It empowers health systems such as Memorial Hermann, Stanford Children’s Health, and New England BaptistHospital as well as radiology practices, subspecialty practices, and clinical research organizations to dramatically improve imaging and collaborative care workflows. | $7.5M / Series A / Nov 04, 2010 | |
|
Vascular Pathways
|
Vascular Pathways, founded by Amir Belson, M.D., is a privately held medical device company focused on commercializing the Rapid IntraVascular Start (RIVS) catheter, an FDA cleared device enabling rapid, safe and successful peripheral IV insertion. | $14M / Series B / Nov 01, 2010 | |
|
OpGen
|
Headquartered in Rockville, Maryland, OpGen (NASDAQ:OPGN) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. OpGen, along with its subsidiaries, Curetis and Ares Genetics, develop and commercialize molecular microbiology solutions to help guide clinicians with morerapid and actionable information about life threatening infections to improve patient outcomes. Our innovative approaches to infectious disease diagnostics consist of highly multiplexed syndromic molecular panels, and next-generation sequencing combined with smart bioinformatics and artificial intelligence to address the global threat of antimicrobial resistance (AMR). By integrating these capabilities, we provide unique rapid molecular diagnostic products and services that help to dramatically transform patient care by using precision medicine to guide antibiotic therapy selection and optimize the treatment of life-threatening drug-resistant infections, improve antibiotic stewardship, and decrease the spread of multidrug-resistant microorganisms (MDROs).OpGen Community (Linkedin Group) provides an accessible environment to share information, exchange questions and best practices using OpGen’s technologies in a variety of applications. | $17M / Series B / Sep 28, 2010 | |
| See all 33 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical VC Funds
16,214 investors
Health Care Investors in United States
21,541 investors
FAQ
What does CHL Medical Partners invest in?
CHL Medical Partners invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series C stage. Most of the 33 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact CHL Medical Partners?
Public channels for CHL Medical Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at CHL Medical Partners?
The team at CHL Medical Partners includes Timothy F.Howe (Founder & Partner) and Jeffrey J. Collinson (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
